Design and Performance Evaluation of Tamsulosin Prolonged Release Matrix Tablets Using Different Polymers

The design and performance evaluation of a prolonged-release matrix tablet formulation of Tamsulosin Hydrochloride, an α-adrenoreceptor blocker frequently recommended for benign prostatic hyperplasia (BPH), are the main objectives of this study. The goal was to find an optimal formulation with improved release kinetics and tablet integrity while achieving prolong drug release using different polymers. The polymeric matrices included different amounts of sodium carboxymethyl cellulose (NaCMC), hydroxypropyl methylcellulose K100 (HPMC K100), ethyl cellulose (45cps), and polyethylene oxide (PEO). Ethyl Cellulose, HPMC K100, and NaCMC were all present in equal concentrations in trials 1 through 3. PEO was added in Trial 4 at a concentration of 100 mg, and in Trial 5, its concentration was raised to 120 mg. Trial 5, which was made utilizing a fluidized bed processor and wet granulation, was determined to be the best formulation because of its excellent matrix integrity and regulated drug release profile. medication crystallinity was preserved by X-ray diffraction (XRD) studies, which showed no significant interaction between the medication and polymers. The modified matrix provided consistent extended release suitable for once-daily dosing, boosting patient compliance. According to this study, PEO is a significant polymer for developing strong, controlled-release oral drug delivery systems for α-adrenoreceptor blockers, such as tamsulosin.